No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ABT241213C133000
- 0.00
- 0.000.00%
15min DelayTrading Dec 11 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest133.00Strike Price0.00Turnover0.00%IV15.15%PremiumDec 13, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Jim Cramer Says 'Keep Owning' This Energy Stock, Abbott Laboratories 'Legal Stuff' Is Behind Them
Oppenheimer Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $130
Oppenheimer Sticks to Its Buy Rating for Abbott Laboratories (ABT)
Why Is Abbott Laboratories (ABT) Among the Best Dividend Kings to Invest In For Safe Dividend Growth?
Insiders At Abbott Laboratories Sold US$3.0m In Stock, Alluding To Potential Weakness
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.